Humacyte, Inc.
HUMA
$3.11
$0.103.32%
| Weiss Ratings | HUMA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | HUMA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Very Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Weak | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | HUMA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.48 | |||
| Price History | HUMA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.65% | |||
| 30-Day Total Return | -27.67% | |||
| 60-Day Total Return | -18.05% | |||
| 90-Day Total Return | -38.66% | |||
| Year to Date Total Return | -39.96% | |||
| 1-Year Total Return | -11.40% | |||
| 2-Year Total Return | 16.04% | |||
| 3-Year Total Return | -51.33% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -69.81% | |||
| 52-Week Low % Change | 9.45% | |||
| Price | HUMA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $9.97 | |||
| 52-Week Low Price | $2.75 | |||
| 52-Week Low Price (Date) | Mar 13, 2025 | |||
| 52-Week High Price (Date) | May 31, 2024 | |||
| Valuation | HUMA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 387.29M | |||
| Enterprise Value | 446.36M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.34 | |||
| Earnings Per Share Growth | 54.99% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | -5.66 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $3.11 | |||
| Enterprise Value/EBITDA (TTM) | -4.24 | |||
| Enterprise Value/EBIT | -3.97 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | HUMA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 119.41M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | HUMA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 919 313 9633 | |||
| Address | 2525 East North Carolina Highway 54 Durham, NC 27713 | |||
| Website | www.humacyte.com | |||
| Country | United States | |||
| Year Founded | 2004 | |||
| Profitability | HUMA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | HUMA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -53.23% | |||
| Return on Equity | -- | |||
| Income Statement | HUMA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -42.81M | |||
| EBITDA (TTM) | -105.28M | |||
| EBIT (TTM) | -112.49M | |||
| Net Income (TTM) | -152.87M | |||
| Net Income Avl. to Common (TTM) | -152.87M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -50.81% | |||
| EPS Diluted (TTM) | -1.34 | |||
| EPS Diluted Growth (Q YOY) | -30.64% | |||
| Balance Sheet | HUMA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 20.57M | |||
| Cash Per Share (Q) | $0.17 | |||
| Total Current Assets (Q) | 23.01M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -63.72M | |||
| Current Ratio (Q) | 1.099 | |||
| Book Value Per Share (Q) | -$0.53 | |||
| Total Assets (Q) | 114.76M | |||
| Total Current Liabilities (Q) | 20.94M | |||
| Total Debt (Q) | 79.64M | |||
| Total Liabilities (Q) | 178.49M | |||
| Total Common Equity (Q) | -63.72M | |||
| Cash Flow | HUMA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -1.66M | |||
| Cash from Financing (TTM) | 62.84M | |||
| Net Change in Cash (TTM) | -29.42M | |||
| Levered Free Cash Flow (TTM) | -58.33M | |||
| Cash from Operations (TTM) | -90.60M | |||
